{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:01:14Z","timestamp":1790078474858,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Helmholtz-Zentrum Dresden - Rossendorf e.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Isocitrate dehydrogenase 1 (IDH1) is a cytosolic NADP\n                      <jats:sup>+<\/jats:sup>\n                      -dependent enzyme involved in cellular redox homeostasis and 2-oxoglutarate (2-OG) metabolism. Glioma-associated mutations in IDH1 confer a neomorphic enzymatic activity, resulting in the production and accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG), which contributes to metabolic and epigenetic alterations in IDH-mutant tumors. Small-molecule inhibitors of mutant IDH1 have emerged as promising therapeutic agents. In parallel, radiolabeled derivatives of these inhibitors are being investigated as potential positron emission tomography (PET) tracers for non-invasive imaging of mutant IDH1. Characterizing the binding of small-molecule radioligands to soluble intracellular proteins such as IDH1, however, presents specific methodological challenges. Appropriate experimental approaches are therefore needed to characterize radioligand binding to IDH1 enzymes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Using several established biochemical and biophysical approaches, we found that the radiofluorinated inhibitor ivosidenib ([\u00b9\u2078F]AG-120) binds specifically to both IDH1 and IDH1\n                      <jats:sup>R132H<\/jats:sup>\n                      at nanomolar radioligand concentrations. However, the investigated approaches yielded method-dependent apparent affinity estimates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings support the use of radioligand-based approaches for characterizing soluble intracellular protein targets, while highlighting the need for assay-specific optimization and careful interpretation of quantitative binding parameters.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-026-00502-7","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:06:30Z","timestamp":1790071590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methods for assessing binding of a small-molecule radioligand to soluble enzyme isocitrate dehydrogenase 1 variants"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-3062","authenticated-orcid":false,"given":"Winnie","family":"Deuther-Conrad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu Hang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"6","key":"502_CR10","first-page":"1412","volume":"27","author":"J Blakeley","year":"2025","unstructured":"Blakeley J, Mohile NA, Messersmith H, Lassman AB, Schiff D, Therapy for Diffuse, A.; Oligodendroglial Tumors in Adults Guideline Expert, P. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update. Neurooncology. 2025;27(6):1412\u20138.","journal-title":"Neurooncology"},{"issue":"1","key":"502_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/0003-2697(83)90427-X","volume":"132","author":"RF Bruns","year":"1983","unstructured":"Bruns RF, Lawson-Wendling K, Pugsley TA. A rapid filtration assay for soluble receptors using polyethylenimine-treated filters. Anal Biochem. 1983;132(1):74\u201381.","journal-title":"Anal Biochem"},{"issue":"7274","key":"502_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739\u201344.","journal-title":"Nature"},{"issue":"2","key":"502_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1074\/jbc.M114.608497","volume":"290","author":"G Deng","year":"2015","unstructured":"Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P, He T, Shi C, Bedel O, McLean LR, Le-Strat F, Zhang Y, Marquette JP, Gao Q, Zhang B, Rak A, Hoffmann D, Rooney E, Vassort A, Englaro W, Li Y, Patel V, Adrian F, Gross S, Wiederschain D, Cheng H, Licht S. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem. 2015;290(2):762\u201374.","journal-title":"J Biol Chem"},{"issue":"14","key":"502_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Ivosidenib: First Global Approval. Drugs. 2018;78(14):1509\u201316.","journal-title":"Drugs"},{"key":"502_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/0006-3002(62)90124-5","volume":"63","author":"JP Hummel","year":"1962","unstructured":"Hummel JP, Dreyer WJ. Measurement of protein-binding phenomena by gel filtration. Biochim Biophys Acta. 1962;63:530\u20132.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"502_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.radonc.2015.08.007","volume":"116","author":"J Kessler","year":"2015","unstructured":"Kessler J, G\u00fcttler A, Wichmann H, Rot S, Kappler M, Bache M, Vordermark D. IDH1(R132H) mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status. Radiother Oncol. 2015;116(3):381\u20137.","journal-title":"Radiother Oncol"},{"key":"502_CR24","doi-asserted-by":"crossref","unstructured":"Kessler J, Hohmann T, G\u00fcttler A, Petrenko M, Ostheimer C, Hohmann U, Bache M, Dehghani F, Vordermark D. Radiosensitization and a less aggressive phenotype of human malignant glioma cells expressing Isocitrate Dehydrogenase 1 (IDH1) mutant protein: dissecting the mechanisms. Cancers (Basel). 2019;11(6).","DOI":"10.3390\/cancers11060889"},{"issue":"4","key":"502_CR14","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00259-023-06515-7","volume":"51","author":"TH Lai","year":"2024","unstructured":"Lai TH, Wenzel B, Duki\u0107-Stefanovi\u0107 S, Teodoro R, Arnaud L, Maisonial-Besset A, Weber V, Moldovan RP, Meister S, Pietzsch J, Kopka K, Juratli TA, Deuther-Conrad W, Toussaint M. Radiosynthesis and biological evaluation of [(18)F]AG-120 for PET imaging of the mutant isocitrate dehydrogenase 1 in glioma. Eur J Nucl Med Mol Imaging. 2024;51(4):1085\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"502_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s42003-021-02743-5","volume":"4","author":"S Liu","year":"2021","unstructured":"Liu S, Abboud MI, John T, Mikhailov V, Hvinden I, Walsby-Tickle J, Liu X, Pettinati I, Cadoux-Hudson T, McCullagh JSO, Schofield CJ. Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1. Commun Biology. 2021;4(1):1243.","journal-title":"Commun Biology"},{"issue":"7","key":"502_CR17","doi-asserted-by":"publisher","first-page":"5279","DOI":"10.1021\/acs.jmedchem.3c00203","volume":"66","author":"S Liu","year":"2023","unstructured":"Liu S, Abboud M, Mikhailov V, Liu X, Reinbold R, Schofield CJ. Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors. J Med Chem. 2023;66(7):5279\u201388.","journal-title":"J Med Chem"},{"issue":"8","key":"502_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"key":"502_CR8","doi-asserted-by":"publisher","first-page":"111062","DOI":"10.1016\/j.jocn.2025.111062","volume":"133","author":"FA McHugh","year":"2025","unstructured":"McHugh FA, Jiang J, Luton H, Parkinson J, Cook R, Newey A, Choi C, Kastelan M, Horsley P, Back M, Drummond J. 2-Hydroxyglutarate magnetic resonance spectroscopy for preoperative IDH molecular profiling \u2013 A review of the literature and real-world clinical translation in a busy neurosurgical neuro-oncology unit. J Clin Neurosci. 2025;133:111062.","journal-title":"J Clin Neurosci"},{"issue":"7","key":"502_CR13","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.3390\/molecules28072890","volume":"28","author":"F Neumaier","year":"2023","unstructured":"Neumaier F, Zlatopolskiy BD, Neumaier B. Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas. Molecules. 2023;28(7):2890.","journal-title":"Molecules"},{"issue":"5897","key":"502_CR4","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I-M, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler. K. W., An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science. 2008;321(5897):1807\u201312.","journal-title":"Science"},{"issue":"21","key":"502_CR18","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1021\/bi200499m","volume":"50","author":"B Pietrak","year":"2011","unstructured":"Pietrak B, Zhao H, Qi H, Quinn C, Gao E, Boyer JG, Concha N, Brown K, Duraiswami C, Wooster R, Sweitzer S, Schwartz B. A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of \u03b1HG. Biochemistry. 2011;50(21):4804\u201312.","journal-title":"Biochemistry"},{"issue":"10","key":"502_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","volume":"18","author":"CJ Pirozzi","year":"2021","unstructured":"Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Reviews Clin Oncol. 2021;18(10):645\u201361.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"4","key":"502_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","volume":"9","author":"J Popovici-Muller","year":"2018","unstructured":"Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, de Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su S-SM, Yen K. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Med Chem Lett. 2018;9(4):300\u20135.","journal-title":"ACS Med Chem Lett"},{"key":"502_CR2","doi-asserted-by":"crossref","unstructured":"Schaff LR, Ioannou M, Geurts M, van den Bent MJ, Mellinghoff IK, Schreck KC. State of the art in low-grade glioma management: insights from isocitrate dehydrogenase and beyond. Am Soc Clin Oncol Educational Book. 2024;44(3): e431450.","DOI":"10.1200\/EDBK_431450"},{"issue":"3","key":"502_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rud\u00e0 R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Reviews Clin Oncol. 2021;18(3):170\u201386.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"5","key":"502_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/1099-1352(200009\/10)13:5<279::AID-JMR506>3.0.CO;2-K","volume":"13","author":"DJ Winzor","year":"2000","unstructured":"Winzor DJ. From gel filtration to biosensor technology: the development of chromatography for the characterization of protein interactions. J Mol Recognit. 2000;13(5):279\u201398.","journal-title":"J Mol Recognit"},{"issue":"1","key":"502_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17\u201330.","journal-title":"Cancer Cell"},{"issue":"8","key":"502_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765\u201373.","journal-title":"N Engl J Med"},{"issue":"11","key":"502_CR23","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/cr.2010.145","volume":"20","author":"B Yang","year":"2010","unstructured":"Yang B, Zhong C, Peng Y, Lai Z, Ding J. Molecular mechanisms of off-on switch of activities of human IDH1 by tumor-associated mutation R132H. Cell Res. 2010;20(11):1188\u2013200.","journal-title":"Cell Res"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00502-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:06:38Z","timestamp":1790075198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-026-00502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00502-7","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"24 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any original studies with human or animal subjects performed by.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"70"}}